Results 41 to 50 of about 28,127 (210)

Thalidomide alleviated IgA nephropathy through “gut-kidney axis”

Linchuang shenzangbing zazhi
Objective Thalidomide has anti-inflammatory, immunomodulatory and renoprotective effects. However, its study in IgA nephropathy has remained scarce. The aim was to explore the role and possible mechanism of thalidomide in IgA nephropathy.
Rui-hua Wang, Zhi-jian Zha, Zi-yang Ye, Ya-feng Li   +3 more
doaj   +1 more source

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

Haematologica, 2012
Background Thalidomide has potent antimyeloma activity, but no prospective, randomized controlled trial has evaluated thalidomide monotherapy in patients with relapsed/refractory multiple myeloma.Design and Methods We conducted an international ...
Martin Kropff, Honorata Giongco Baylon, Jens Hillengass, Tadeusz Robak, Roman Hajek, Peter Liebisch, Stefan Goranov, Cyrille Hulin, Joan Bladé, Tommaso Caravita, Herve Avet-Loiseau, Thomas M. Moehler, Claire Pattou, Lela Lucy, Elisabeth Kueenburg, Axel Glasmacher, Robert Zerbib, Thierry Facon   +17 more
doaj   +1 more source

Protective Effect of Thalidomide on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis in Rats via the Inhibition of T Helper 17 Cells

Canadian Journal of Gastroenterology and Hepatology, 2020
Objective. To observe the effects of thalidomide on 2,4,6-trinitrobenzenesulfonic acid- (TNBS-) induced experimental colitis in rats and to explore the possible mechanism of thalidomide in the treatment of CD. Methods.
Ying Xie, Dandan Li, Xiaoshuang Luan, Shuang Jin, Bo Yan, Feng Tian   +5 more
doaj   +1 more source

Thalidomide attenuates the hyporesponsiveness of isolated atria to chronotropic stimulation in BDL rats: The involvement of TNF-α, IL-6 inhibition, and SOCS1 activation [PDF]

Iranian Journal of Basic Medical Sciences, 2019
Objective(s): Cirrhotic cardiomyopathy is a complication of uncured cirrhosis which is associated with hyporesponsiveness of the heart to sympathetic stimulation. The enhancement of portal pressure, nitric oxide (NO) level, pro-inflammatory mediators and
Ali Hosseini-chegeni, farahnaz Jazaeri, Aliakbar Yousefi-Ahmadipour, Mansour Heidari, Alireza Abdollahi, Ahmad Reza Dehpour   +5 more
doaj   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Thalidomide in treatment of connective diseases and vasculities

Reumatismo, 2011
Thalidomide is an immunomodulatory, anti-inflammatory and anti-angiogenic drug. Thalidomide exerts its effects by decreasing circulating CD4 positive T-cells and stimulating CD8 positive T-cells, by increasing the number of Natural Killer cells and T ...
D. Ribatti, F.P. Cantatore, N. Maruotti
doaj   +1 more source

Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study

International Journal of Infectious Diseases, 2021
Objectives: The aim was to evaluate the safety and effectiveness of thalidomide, an immunomodulatory agent, in combination with glucocorticoid, for the treatment of COVID-19 patients with life-threatening symptoms.
Yuping Li, Keqing Shi, Feng Qi, Zhijie Yu, Chengshui Chen, Jingye Pan, Gaojun Wu, Yanfang Chen, Ji Li, Yongping Chen, Tieli Zhou, Xiaokun Li, Jinglin Xia   +12 more
doaj   +1 more source

Characteristics and temporal trends of EU teratological safety signals and information dissemination to healthcare professionals in the Netherlands—A contribution of the ConcePTION project

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Although regulatory responses to safety signals have been studied, pregnancy‐specific data and their dissemination to medical professionals remain unclear. This study examined the characteristics and temporal trends of teratological safety signals prompting the European Medicines Agency to implement risk minimization measures.
Yrea R. J. van Rijt‐Weetink, Rosanne E. Huisman, Jan‐Peter van Wieringen, H. J. M. J. (Ineke) Crijns, Florence P. A. M. van Hunsel, Anneke L. M. Passier, Sander Borgsteede, A. C. G. (Toine) Egberts, Laura M. Yates, Eugène P. van Puijenbroek   +9 more
wiley   +1 more source

Thalidomide in cancer

Biomedicine & Pharmacotherapy, 2002
Thalidomide has immunomodulatory and anti-angiogenic properties which may underlie its activity in cancer. After its success in myeloma, it has been investigated in other plasma cell dyscrasias, myelodysplastic syndromes, gliomas, Kaposi's sarcoma, renal cell carcinoma, advanced breast cancer, and colon cancer. Thalidomide causes responses in 30-50% of
S, Singhal, J, Mehta
openaire   +2 more sources

Drug‐coated balloons: From conventional designs to next‐generation innovations in vascular therapy

BMEMat, EarlyView.
This review traces the evolution of drug‐coated balloons (DCBs) from conventional designs to next‐generation platforms. We highlight innovations in balloon engineering, coating technologies, and therapeutic agents that enhance localized drug delivery while addressing challenges in efficiency, safety, and biocompatibility for vascular and emerging non ...
Lu Zhang, Jiawei Cui, Jin Wang, Manfred F. Maitz, Rifang Luo, Yunbing Wang   +5 more
wiley   +1 more source